FDA Approves Zynyz for the Treatment of Metastatic
March 22, 2023Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
March 22, 2023March 22, 2023 - Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved Rezzayo (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Rezzayo is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.
The FDA approval of once-weekly Rezzayo was based on clinical data from Cidara’s global ReSTORE Phase 3 trial and supported by the STRIVE Phase 2 clinical trial and extensive non-clinical development program.
Rezzayo is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.